For ESA therapy in patients with solid tumors and hematologic malignancies, the guidelines recommend a target Hb level of 12 g/dL, initiated at <10 g/dL (symptomatic anemia) or <8 g/dL (asymptomatic anemia). The gene discussed is GSTM1; the disease is anemia.